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Abstract
Ten new triterpenoids, camphoratins A–J (1–10), along with 12 known compounds were isolated
from the fruiting body of Taiwanofungus camphoratus. Their structures were established by
spectroscopic analysis and chemical methods. Compound 10 is the first example of a naturally
occurring ergosteroid with an unusual cis-C/D ring junction. Compounds 2–6 and 11 showed
moderate to potent cytotoxicity with EC50 values ranging from 0.3 to 3 μM against KB and KB-
VIN human cancer cell lines. Compounds 6, 10, 11, 14–16, 18, and 21 exhibited anti-
inflammatory NO-production inhibition activity with IC50 values of less than 5 μM, which was
more potent than the nonspecific NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME).
Taiwanofungus camphoratus (synonym: Ganoderma camphoratum; Antrodia cinnamomea;
Antrodia camphorata) (Polyporaceae, Aphyllophorales), is a rare and precious medical
fungus in Taiwan and is called a “national treasure of Taiwan”.1 Its Chinese name is Zhan-
Ku or Niu-Chang-Chih. The microorganism is parasitic to the inner heart-wood wall of old
hollow trunks of Cinnamomum kanehirai Hay. (Lauraceae). The growth rate of natural T.
camphoratus in the wild is very slow, and it is difficult to cultivate in a greenhouse, making
fruiting bodies expensive to obtain. In traditional Taiwanese folk medicine T. camphoratus
has been used as an important health food for treating food, alcohol, and drug intoxication,
*Corresponding authors: Tel: 919-962-0066. Fax: 919-966-3893. khlee@unc.edu; tswu@mail.ncku.edu.tw.
†Chung Hua University of Medical Technology.
‡Chang Gung University.
§Department of Chemistry, National Cheng Kung University.
⊥Neurophysiology Laboratory, National Cheng Kung University Medical Center and Medical School.
||National Research Institute of Chinese Medicine.
∇China Medical University and Hospital.
○University of North Carolina.
+These authors contributed equally to this work.




J Nat Prod. Author manuscript; available in PMC 2011 November 29.
Published in final edited form as:













diarrhea, abdominal pain, hypertension, itching, and liver cancer.2 Previous studies on the
chemical constituents of the fruiting body of T. camphoratus showed that it is a rich source
of triterpenoidic acids, some of which have shown anti-inflammatory,3 anticholinergic,4 and
antiserotonergic activities.4 Furthermore, zhankuic acids A and C exhibited significant
cytotoxicity against P-388 murine leukemia cells in vitro.4 The present study on the
chemical constituents of an EtOH extract of the fruiting body of T. camphoratus has led to
the isolation of 10 new triterpenoids, namely camphoratins A–J (1–10), and 12 known
compounds, including zhankuic acids A–C (11–13),4,5 zhankuic acid A methyl ester (14),4
antcin A (15),5 antcin C (16),5 antcin K (17),6 methyl antcinate H (18),7 eburicol (19),8
ergosterol D (20),9 methyl 4α-methylergost-8,24(28)-diene-3,11-dion-26-oate (21),10 and
ergosterol peroxide (22).11 Cytotoxic activity, inhibition of nitric oxide (NO) or reactive
oxygen species (ROS) production, and free radical-scavenging activity of the isolates were
evaluated in our study.
Results and Discussion
Camphoratin A (1) was obtained as a colorless powder. The HRESIMS of 1 showed a
pseudomolecular ion peak at m/z 511.3038, consistent with a molecular formula of
C29H44O6Na, and eight degrees of unsaturation. The UV and IR absorption bands at 255 nm
and 1709, 1660, and 3408 cm−1, respectively, suggested the presence of α,β-unsaturated
carbonyl and carboxylic acid functionalities. The former was corroborated by carbon
resonances at δ 202.8 (qC), 154.3 (qC), and 141.2 (qC), and the latter was evidenced by the
resonance at δ 176.9 (qC). An exocyclic double bond was also identified from the NMR
signals at δC 150.7 (qC), 110.5 (CH2) and δH 5.07, 5.23 (each 1H, s). The above data,
coupled with the characteristic methyl signals at δH 0.90 (3H, s), 1.11 (3H, d, J = 7.6 Hz),
1.18 (3H, d, J = 6.8 Hz), 1.48 (3H, d, J = 7.2 Hz), and 1.57 (3H, s), suggested a 4-methyl-
ergost-8-en-11-one skeleton similar to that of antcin C (16).5 The 3α-OH functionality was
deduced by the correlations from H-3 (δ 3.89, 1H, d, J = 1.6 Hz, β-orientation) to C-4 and
C-1 and from H3-29 to C-3, C-4, and C-5 in the HMBC spectrum of 1. The hydroxy groups
attached at C-7 and C-12 were further designated by the correlations from H-7 (δ 4.52, 1H, t,
J = 8.4 Hz) to C-6 and C-8 and from H-12 (4.44, 1H, s) to C-13, C-14, and C-17,
respectively. The C-25 carboxylic functionality was assigned due to the presence of an
HMBC correlation from H-25 (δ 3.45, 1H, q, J = 6.8 Hz) to the carbon resonance at δ 176.9.
A comparison of the NMR spectroscopic data of 1 with those of 165 confirmed the above
elucidation and unambiguously established the structure of 1. The relative configuration of 1
was determined by the NOE correlations observed in a NOESY experiment. In the NOESY
spectrum of 1, H-7 showed NOE enhancements with both H-5 and H-14, suggesting that
these protons had α-orientations. Furthermore, NOE correlations between H-3 and H-4 as
well as between H-12 and H3-18 disclosed that these protons are β-oriented.
Camphoratin B (2) was obtained as a colorless syrup. The HRESIMS of 2 gave an [M +
Na]+ peak at m/z 495.3089 and established the molecular formula C29H44O5Na, which is 16
mass units less than that of 1. The 1H NMR and 13C NMR spectroscopic data of 2 were
similar to those of 16 except for the presence of a 3α-OH in 2 rather than a carbonyl group
in 16. The data were also similar to those of 1 except that the hydroxy-containing methine
(C-12) in 1 was replaced by a methylene group in 2. This assignment was confirmed by the
significant up-field shift of H-14 (δ 2.66, 1H, dd, J = 12.0, 6.0 Hz) in 2, relative to that in 1
(δ 3.57, 1H, dd, J = 12.0, 6.8 Hz), due to the absence of a quasi 1,3-diaxial interaction
between H-14 and 12α-OH. In addition, the HMBC correlations from H2-12 to C-11, C-13,
C-14, and C-18 further demonstrated the above elucidations.
Camphoratin C (3) was obtained as a colorless powder and was found to possess the
molecular formula, C29H42O6Na, as deduced from the HRESIMS and NMR data. Its IR
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spectrum showed the presence of hydroxy (3411 cm−1), carboxylic acid (1707 cm−1), and
conjugated carbonyl (1674 cm−1) groups. The UV spectrum showed similar absorption
bands to those of 11–13,4 which indicated the presence of an 8(9)-en-7,11-dione moiety.
This assignment was further corroborated by the carbon resonances at δ 203.05 (qC), 203.0
(qC), 155.0 (qC), and 144.2 (qC). A comparison of NMR spectroscopic data of 3 with those
of 176 revealed identical substitution at C-3 and C-4, while the C-7 hydroxy group in 17 was
oxidized to a carbonyl moiety in 3.
Camphoratin D (4) was isolated as a colorless powder and exhibited an [M + Na]+ peak at
m/z 509.2875, corresponding to a molecular formula of C29H42O6Na as obtained from
HRESIMS. Its IR spectrum showed the presence of hydroxy (3444 cm−1), carbonyl (1708
cm−1), and conjugated ketone (1674 cm−1) groups. The UV spectrum showed absorption
bands at 246 nm, suggesting the presence of an 8(9)-en-11-one moiety,5 which was
corroborated by the carbon resonances at δ199.5 (qC), 154.3 (qC), and 141.2 (qC). The
proton resonance at δ 4.98 (1H, t, J = 8.4 Hz) was attributed to the 7β hydroxy functionality.
The other carbonyl carbon resonance at δ 211.0 was assigned to C-3 due to the observation
of HMBC correlations from H3-29 to C-3, C-4, and C-5. The side chain moiety was found to
be the same as that in 1–3. Moreover, a hydroxy-containing quaternary carbon was assigned
at C-14 according to the downfield shift of C-15 as compared to the corresponding carbon in
1–3. In the 13C NMR spectrum of 4, the significant upfield shift for C-12 (Δ = –9.4 ppm)
and C-17 (Δ = –5.5 ppm) as well as the downfield shift for C-18 (Δ = +3.9 ppm), relative to
those in 2 (C-12, δ 58.9; C-17, δ 55.0), suggested an α-orientation for 14-OH.7,12
Camphoratin E (5), a colorless syrup, was found to possess the molecular formula
C30H44O5, as deduced from the HRESIMS and NMR spectroscopic data. Its IR spectrum
showed the presence of hydroxy (3491 cm−1), ester (1730 cm−1), and conjugated carbonyl
(1678 cm−1) groups. The UV absorption band at νmax 260 nm and carbon resonances at δ
203.1 (qC), 202.1 (qC), 153.7 (qC), and 144.7 (qC) indicated the presence of an 8(9)-
ene-7,11-dione moiety. The NMR spectroscopic data of 5 were similar to those of 124
except for additional methoxy signals at δH 3.66 and δC 51.9, which suggested that 5 is the
methyl ester of 12. In the 13C NMR spectra of 5, several smaller signals at δC 31.0, 45.5, and
16.3 revealed the presence of an epimeric mixture at C-25.4
The HRESIMS of camphoratin F (6) established the same molecular formula, C30H44O5, as
that of 5. Its UV and IR spectra showed the presence of an 8(9)-en-11-one moiety (λmax 251
nm and νmax 1669 cm−1), a carbonyl group (1711 cm−1), and an ester moiety (1735 cm−1).
Comparison of the NMR data of 6 and 5 showed that the hydroxy-linked methine resonance
of H-3 in 5 was absent from the NMR spectrum of 6, and replaced by a carbonyl
functionality at δC 212.3. In addition, the carbon resonance for the C-7 carbonyl group in 5
was converted to a hydroxy-linked methine (δH 4.39, 1H, t, J = 8.0 Hz) in 6. A β-orientation
of the hydroxy group at C-7 was deduced by the splitting pattern of H-7 as compared to
those in 1 and 2. Similarly to 5, the NMR data of 6 showed the presence of an epimeric
mixture at C-25 (Table 1).
Camphoratin G (7) was found to have the molecular formula C29H42O5, 14 mass units less
than 6, as deduced from the HRESIMS and NMR data. The UV and IR spectra of 7 were
similar to those of 6, except that a carboxylic acid moiety was observed in 7 (νmax 1707
cm−1) rather than an ester group. Consequently, the structure of 7 might be structurally
related to 6. Comparison of 1H NMR data of 7 with those of 6, antcin F, and methyl
antcinate G,7 disclosed that 7 might be a C-7 epimer of antcin F. Moreover, the splitting
pattern of H-7 (d, J = 2.0 Hz) in 7 suggested a β-oriented proton7 rather than an α-proton
like those in 1, 2, and 6.
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The HRESIMS of camphoratin H (8) gave a pseudomolecular ion peak at m/z 447.3237 [M
+ Na]+, corresponding to the molecular formula C29H44O2Na. Its UV and IR spectra showed
the presence of an 8(9)-en-11-one moiety (λmax 248 nm and νmax 1678 cm−1) and a carbonyl
group (1711 cm−1). Its 1H NMR spectrum displayed signals for six methyl groups at δH 0.74
(s), 0.95 (d), 1.03 (d), 1.06 (d), 1.29 (d), and 1.34 (s). The above data coupled with the
absence of the carbon resonance appropriate for a carboxylic acid or a methyl ester moiety
suggested that 8 possesses a 4-methyl-ergost-8-en-11-one skeleton. The NMR spectra of 8
were similar to those of 15,5 except that the NMR signals appropriate for a carboxylic
functionality were replaced by signals for a C-25 methyl group.
Camphoratin I (9) was found to have the molecular formula C28H44O2 from HRESIMS
analysis. The absence of UV absorption bands from 240 to 270 nm disclosed that 9 did not
possess an 8(9)-en-7,11-dione or 8(9)-en-11-one moiety. The IR and 13C NMR data of 9
showed the presence of 28 carbon signals, including one carbonyl group (δ 211.9, νmax 1716
cm−1), two double bonds (δ 139.4, 117.1, 136.7, and 130.4), and one hydroxymethyl moiety
(δ 66.9, νmax 3336 cm−1). The above data, coupled with the characteristic methyl signals at
δH 0.57 (3H, s), 0.86 (3H, d, J = 6.8 Hz), 1.00 (3H, d, J = 6.8 Hz), 1.01 (3H, s), and 1.02
(3H, d, J = 7.2 Hz), suggested that 9 is similar to the known compound ergost-7-en-3-one.13
By comparison of the 13C NMR spectroscopic data of 9 with those of ergost-7-en-3-one, it
was found that resonances for the nucleus of both compounds were superimposable,
revealing that they have different substitution patterns in the side chain moiety. This was
confirmed by the HMBC correlations from H3-21 to C-17, C-20, and C-22, from H3-28 to
C-23, C-24, and C-25, and from H3-27 to C-24, C-25, and C-26. Comparison of the NMR
data of C-24, C27, and C-28 of 9 with those of synthetic compounds led to the establishment
of an erythro configuration at C-24 and C-25 (24S, 25S or 24R, 25R). Furthermore, the 24S,
25S configuration for 9 was confirmed by the preparation of its (R)-MTPA ester, in which
the proton resonance of H2-26 showed a broad doublet at δ 4.17.14 In addition, the MTPA
ester helped to establish the E geometry of C-22–C-23 double bond by a 15.0 Hz coupling
constant.
The molecular formula of camphoratin J (10) was assigned as C30H44O4 based on its
HRESIMS. Its UV and IR spectra showed the presence of an 8(9)-en-11-one moiety (λmax
250 nm and νmax 1669 cm−1), a carbonyl group (1709 cm−1), and an ester moiety (1738
cm−1). The 8(9)-en-11-one moiety was deduced by the carbon resonances at δ 200.4, 138.0,
and 154.6 and HMBC correlations from H2-12 to the carbonyl carbon. The carbonyl and
methyl ester functionalities were assigned at C-3 and C-25, respectively, based on the
HMBC correlations from H3-29 to C-3, C-4, and C-5 and from H-25 to the carbon resonance
at δ 175.0, which was also correlated with the methoxy group at δH 3.66 (3H, s). The
inspection of the 2D NMR spectra led to the establishment of the same planar structure as
the known compound methyl 4α-methylergost-8,24(28)-diene-3,11-dion-26-oate.10
However, both compounds differed in carbon resonances for rings C and D, revealing the
presence of epimers at the C/D ring junction. The relative configuration of the C/D ring
junction in 10 was elucidated by the NOE enhancements observed in a selective 1D NOESY
experiment. Irradiation of H3-18 caused enhancements of H-14, H-20, and H3-21, but not of
H-17, suggesting a cis-fused C/D ring. The downfield shift (Δ = +10.4 ppm) of C-18 in
the 13C NMR spectrum of 10, relative to that observed for methyl 4α-
methylergost-8,24(28)-dien-3,11-dion-26-oate, was also in agreement with a rare cis C/D
ring junction, which has been found in compounds from marine sponges.15–17 Additional
smaller carbon signals at δC 31.8, 45.5, and 16.3 were attributed to the other C-25 epimer.
Compound 10 represents the first ergosteroid with cis-fused C/D ring junction.
The cytotoxicity of the new and known compounds (1–19) was evaluated in parallel with
etoposide against the human cancer cell line KB and multidrug-resistant strain KB-VIN in
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vitro (Table 4). Several of the compounds, including 2–7, 11–13, and 15, showed moderate
to potent cytotoxic activity with EC50 values ranging from 0.3 to 15.5 μM. Compounds 3
and 5 showed the highest cytotoxicity against the KB cell line with EC50 values of 0.3 and
0.45 μM, respectively. Compounds 4 and 6 also showed cytotoxicity against KB with EC50
values of 1.0 and 2.0 μM, respectively. More importantly, compounds 4 and 6 retained their
activity against multi-resistant strain KB-VIN with EC50 values of 1.4 and 2.9 μM,
respectively. It appeared that 4 and 6 were not substrates of P-glycoprotein (P-gp), a key
transporter related to drug-resistance, based on the lack of cross-resistance shown by KB-
VIN. By comparison, etoposide, a known P-gp substrate, was at least eight-fold less active
in the KB-VIN cell line. Comparing the structures of compounds 3–6, we find that 3 and 5
contain the same C-3 α-hydroxy group and C-7 keto moiety, while 4 and 6 contain a C-3
keto and C-7 β-hydroxy group. It seems that the latter triterpene scaffold may overcome the
resistance issue. Compound 3 has an additional C-4 β-hydroxy group and a free carboxylic
acid tail in its R5 moiety, which may contribute to the best activity profile of the series.
The anti-inflammatory activities of 2, 6, 9, and 10–22 were evaluated by examining their
effects on lipopolysaccharide (LPS)-induced inducible-nitric oxide synthase (iNOS)-
dependent NO production and NADPH oxidase (NOX)-dependent ROS production in
murine microglial cells (BV2) and peripheral human neutrophils (PMN). Compounds 6, 10,
11, 14–16, 18, and 21 significantly inhibited NOS activity with IC50 values of 2.5, 1.6, 3.6,
0.6, 4.1, 4.2, 2.5, and 1.5 μM, respectively. They were more potent than Nω-nitro-L-arginine
methyl ester (L-NAME) (IC50 25.8 μM), a nonspecific NOS inhibitor, at inhibiting LPS-
induced NO production (Table 5). The remaining compounds, except for 20, inhibited NOS
activity with IC50 values ranging from 6.3 to 22.3 μM (Table 5). NOX is the major ROS-
producing enzyme in activated inflammatory cells.18 We previously reported that drugs with
anti-inflammatory activity also show potent NOX-inhibitory action.19,20 Therefore, we
evaluated the isolates for effects on NOX activity in lysates of microglial cells and PMN.
Our data suggest that none of the tested compounds were potent inhibitors of NOX in lysates
of microglial cells and PMN, relative to the specific NOX inhibitor diphenyleneiodonium
(DPI) (IC50 0.4 and 0.3 μM, respectively) (Table 5). In addition, the free radical-scavenging
capacities of these compounds were examined in a cell-free 1,1-diphenyl-2-picrylhydrazyl
(DPPH) solution. None of the tested compounds showed significant free radical-scavenging
activity.
Although it is now clear that proliferation of cells alone does not cause cancer, sustained cell
proliferation in an environment rich in inflammatory cells, growth factors, activated stroma,
and DNA-damage-promoting agents, certainly potentiates and/or promotes neoplastic risk.
21 In many circumstances, inflammation orchestrates the microenvironment around tumors,
contributing to proliferation, survival, and migration. Cancer cells also use selectins,
chemokines, and their receptors (involved in inflammatory response) for invasion,
migration, and metastasis. Interestingly, Peng et al. found that a crude extract of Antrodia
camphorata (Taiwanofungus camphoratus) significantly inhibited proliferation of three
transitional cell carcinonoma (TCC) cell lines (RT4, a superficial cancer cell line and
TSGH-8301, T24, two metastatic cancer cell lines), likely through different mechanisms.22
Combined with our observations in this study, it would be interesting to evaluate whether
the antitumor invasion effect in the crude extract could be mediated through the anti-
inflammatory properties of the contained triterpenoids. Thus, the newly identified
camphoratin analogs with both potent cytotoxicity and anti-inflammatory activity merit
further investigation as cancer chemotherapeutic agents or as anti-inflammatory drugs for
the treatment of NO-dependent neurodegenerative disorders.
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Melting points were determined on a Yanagimoto MP-S3 micro-melting point apparatus. IR
spectra were recorded on a Shimazu Prestige-21 FTIR spectrometer. Optical rotations were
measured using a Jasco DIP-370 Polarimeter. UV spectra were obtained on a Hitachi
UV-3210 spectrophotometer. ESI and HRESI mass spectra were recorded on a Bruker
APEX II mass spectrometer. The NMR spectra, including 1H NMR, 13C NMR, COSY,
NOESY, HMBC, and HMQC experiments, were recorded on Bruker AVANCE-500 and
AMX-400. Silica gel (E. Merck 70–230, 230–400 mesh) was used for column
chromatography.
Fungal Material
Wild fruiting bodies of T. camphoratus, which grew in Ping-Tung County, Taiwan, were
purchased from the Kaohsiung Society for Wildlife and Nature in 2003. The fungus was
identified by Dr. Tun-Tschu Chang (Taiwan Forestry Research Institute). A voucher
specimen (TSWu 2003005) was deposited in the Department of Chemistry, National Cheng
Kung University, Tainan, Taiwan.
Extraction and Isolation
The fruiting body of T. camphoratus (1.0 kg) was extracted with EtOH (4 × 10 L) under
reflux for 8 h. The EtOH extract was concentrated to afford a brown syrup (161 g) and then
partitioned between H2O and n-hexane. The n-hexane layer (9.3 g) was chromatographed on
silica gel and eluted with EtOAc in n-hexane (0–100% of EtOAc, gradient) to obtain 10
fractions. Fraction 4 was rechromatographed on a silica gel column using n-hexane–Me2CO
(19:1) as eluent to yield 8 (3.0 mg), 9 (6.0 mg), 10 (4.5 mg), 19 (22.0 mg), 20 (90.2 mg), 21
(22.1 mg), and 22 (16.5 mg). Compound 22 (41.1 mg) was obtained in the same way from
fraction 8. The water layer (145 g) was filtered and concentrated under reduced pressure to
give a brown syrup (55 g) and a water-insoluble portion (89 g). The water-insoluble portion
was chromatographed on a silica gel column using CHCl3–MeOH mixtures of increasing
polarity for elution to obtain 10 fractions (WI-1–WI-10). Compounds 1 (2.2 mg), 5 (2.0 mg),
6 (14.2 mg), 9 (1.0 mg), 14 (1.29 g), 15 (53.8 mg), and 21 (62.2 mg) were obtained from a
combined fraction (fractions WI-1 and WI-2) by silica gel column chromatography with
gradient elution (CHCl3–Me2CO, 39:1 to 14:1). Fraction WI-3 was separated on a silica gel
column using i-Pr2O–MeOH (19:1) as the eluent to yield 11 (141.5 mg), 18 (11.0 mg), 16
(122.9 mg), and 12 (53.0 mg). Fraction WI-4 was chromatographed on a silica gel column
with i-Pr2O–MeOH (12:1) to give 7 (11.3 mg), 18 (38.0 mg), 16 (708.0 mg), and 12 (66.5
mg). Compounds 2 (5.0 mg), 4 (2.2 mg), 7 (3.4 mg), and 13 (286.2 mg) were obtained from
fraction WI-5 using silica gel column chromatography (eluent, CHCl3–MeOH, 12:1).
Fractions WI-6 and WI-7 were combined and rechromatographed on a silica gel column
with CHCl3–MeOH (6:1) as the mobile phase to afford 3 (3.8 mg) and 13 (1.81 g).
Compound 17 (1.16 g) was isolated from a combined fraction (fractions WI-8 and WI-9) by
silica gel column chromatography using i-Pr2O–MeOH (4:1) as the eluent.
Camphoratin A (3α,7β,11α-trihydroxy-11-oxo-4α-methylergosta-8,24(28)-
dien-26-oic acid, 1)—colorless powder (MeOH); mp 117–119 °C; [α] D 25 +221 (c 0.001,
MeOH); UV (MeOH) λmax(log ε) 255 (3.49) nm; IR (KBr) νmax 3408, 2959, 2930, 2875,
1709, 1660, 1215, 1059 cm−1; 1H NMR and 13C NMR, see Table 1 and 2; ESIMS m/z 511
[M + Na]+; HRESIMS m/z 511.3038 (calcd for C29H44O6Na 511.3035).
Camphoratin B (3α,7β-dihydroxy-11-oxo-4α-methylergosta-8,24(28)-dien-26-
oic acid, 2)—colorless syrup; [α]D 25 +54 (c 0.006, MeOH); UV (MeOH) λmax (log ε) 255
Wu et al. Page 6













(3.79) nm; IR (KBr) νmax 3420, 2962, 2935, 2878, 1709, 1659, 1217, 1083 cm−1; 1H NMR
and 13C NMR, see Table 1 and 2; ESIMS m/z 495 [M + Na]+; HRESIMS m/z 495.3089
(calcd for C29H44O5Na 495.3086).
Camphoratin C (3α,4β-dihydroxy-7,11-dioxo-4α-methylergosta-8,24(28)-
dien-26-oic acid, 3)—colorless powder (MeOH); mp 186–188 °C; [α]D 25 +57 (c 0.067,
MeOH); UV (MeOH) λmax (log ε) 271 (3.80) nm; IR (KBr) νmax 3411, 2966, 2936, 2878,
1709, 1674, 1230, 1062 cm−1; 1H NMR and 13C NMR, see Table 1 and 2; ESIMS m/z 509
[M + Na]+; HRESIMS m/z 509.2874 (calcd for C29H42O6Na 509.2879).
Camphoratin D (7β,14α-dihydroxy-3,11-dioxo-4α-methylergosta-8,24(28)-
dien-26-oic acid 4)—colorless powder (MeOH); mp 175–177 °C; [α]D 25 +34° (c 0.004
MeOH); UV (MeOH) λmax (log ε) 246 (3.97) nm; IR (KBr) νmax 3444, 2971, 2936, 2878,
1708, 1670, 1229, 1187, 1068, cm−1; 1H NMR and 13C NMR, see Table 1 and 3; ESIMS m/
z 509 [M + Na]+; HRESIMS m/z 509.2875 (calcd for C29H42O6Na 509.2879).
Camphoratin E (methyl 3α-hydroxy-7,11-dioxo-4α-methylergosta-8,24(28)-
dien-26-oate, 5)—colorless syrup; [α]D 25 +166 (c 0.007, MeOH); UV (MeOH) λmax
(logε) 260 (3.68) nm; IR (KBr) νmax 3491, 2959, 2936, 2877, 1730, 1678, 1235, 1202, 1169
cm−1; 1H NMR and 13C NMR, see Table 1 and 3; ESIMS m/z 507 [M + Na]+; HRESIMS
m/z 507.3088 (calcd for C30H44O5Na 507.3086).
Camphoratin F (methyl 7β-hydroxy-3,11-dioxo-4α-methylergosta-8,24(28)-
dien-26-oate, 6)—colorless powder (MeOH); mp 100–101 °C; [α]D 25 +174 (c 0.008,
MeOH); UV(MeOH) λmax (log ε) 251 (4.05) nm; IR (KBr) νmax 3386, 2967, 2877, 1732,
1711, 1669, 1235, 1197, 1167, 1083 cm−1; 1H NMR and 13C NMR, see Table 1 and 3;
ESIMS m/z 507 [M + Na]+; HRESIMS m/z 507.3083 (calcd for C30H44O5Na 507.3086)
Camphoratin G (7α-hydroxy-3,11-dioxo-4α-methylergosta-8,24(28)-dien-26-oic
acid, 7)—colorless powder (MeOH); mp 196–198 °C; [α]D 25 +139 (c 0.007, MeOH); UV
(MeOH) λmax (log ε) 247 (4.33) nm; IR (KBr) νmax 3420, 2964, 2930, 2875, 1707, 1659,
1171 cm−1; 1H NMR and 13C NMR, see Table 1 and 3; ESIMS m/z 493 [M + Na]+;
HRESIMS m/z 493.2929 (calcd for C29H42O5Na 493.2930).
Camphoratin H (4α-methylergosta-8,24(28)-dien-3,11-dione, 8)—colorless syrup;
[α]D25 +41 (c 0.008, MeOH); UV (MeOH) λmax (log ε) 248 (3.94) nm; IR(KBr) νmax 2965,
2940, 2877, 1711, 1678 cm−1; 1H NMR and 13C NMR, see Table 1 and 3; ESIMS m/z 447
[M + Na]+; HRESIMS m/z 447.3237 (calcd for C29H44O2Na 447.3239).
Camphoratin I [(25S)-26-hydroxy-ergosta-7,22-dien-3-one, 9]—colorless powder
(MeOH); mp 192–193 °C; [α]D 25 +128 (c 0.003, MeOH); IR (KBr) νmax 3336, 2956, 2873,
1716, 1024 cm−1; 1H NMR and 13C NMR, see Table 1 and 3; ESIMS m/z 435 [M + Na]+;
HRESIMS m/z 435.3242 (calcd for C28H44O2Na 435.3239).
Camphoratin J (methyl 3,11-dioxo-4α-methyl-14β-ergosta-8,24(28)-dien-26-
oate, 10)—colorless needles (MeOH); mp 100–102 °C; [α]D 25 +164 (c 0.005, MeOH); UV
(MeOH) λmax (logε) 250 (4.35) nm; IR (KBr) νmax 2953, 2873, 2856, 1738, 1709,
1669,1460, 1453, 1375, 1077 cm−1; 1H NMR and 13C NMR, see Table 1 and 3; ESIMS m/z
491 [M+Na]+; HRESIMS m/z 491.3135 (calcd for C30H44O4Na 491.3137).
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Preparation of (R)-MTPA Ester of 9
To a solution of 9 (0.5 mg) in pyridine (0.4 mL) was added (S)-MTPA chloride (25 μL), and
the mixture was allowed to stand for 3 h at room temperature. The reaction was quenched by
the addition of 1.0 mL of H2O, and the mixture was subsequently extracted with EtOAc (3 ×
1.0 mL). The EtOAc-soluble layers were combined, dried over anhydrous MgSO4, and
evaporated. The residue was subjected to silica gel column chromatography using n-hexane–
EtOAc (4:1) as the eluent to yield the (R)-MTPA ester, 9a (0.7 mg). Selective 1H NMR (500
MHz, CDCl3) of 9a: δ 7.38–7.53 (5H, m, Ph), 5.21 (1H, dd, J = 15.0, 7.5 Hz, H-23), 5.16
(1H, dd, J = 15.0, 7.5 Hz, H-22), 4.17 (2H, br d, J = 6.4 Hz, H2-26), 3.54 (3H, s, OMe), 1.02
(3H, d, J = 6.5Hz, H3-21), 1.01(3H, s, H3-19), 0.95 (3H, d, J = 7.0 Hz, H3-28), 0.85 (3H, d,
J =7.0 Hz, H3-27), 0.57 (3H, s, H3-18).
In vitro Cytotoxicity Assay
The KB-MDR cell line system was a generous gift from Professor Y.-C. Cheng, Yale
University and was developed using step-wise vincristine selection as reported.23 The MDR
cell-line KB-VIN and the parent KB nasopharyngeal were propagated in RPMI-1640
medium supplemented with 25mM HEPES, 10% fetal bovine serum, and 100 U/mL
penicillin G, 100 μg/mL streptomycin, 250 ng/mL amphotericin B and cultured at 37 °C in a
humidified atmosphere of 95% air/5% CO2. KB-VIN cells were challenged with 0.5 μg/mL
vincristine every two weeks and drug was removed at least one day prior to using the cells.
For the anti-proliferation assay, trypsinized cells were seeded in 96-well microplates at
densities of 5000 cells per well with compounds added from DMSO-diluted stock to give a
dose-range of 20 down to 0.16 μM. After 3 days in culture, attached cells were fixed in situ
with 10% trichloroacetic acid and then stained with 0.4% sulforhodamine B (SRB) in 1%
HOAc.24 The absorbance at 562 nm was measured using a microplate reader after
solubilizing the bound dye. Results were plotted using Prizm software (GraphPad, San
Diego CA). The mean EC50 is the concentration of agent interpolated from graphical results
that caused a 50% reduction in the cell number of treated versus untreated cells and is an
average from at least two independent determinations; variation was less than 5% of the
mean.
Microglial Cell Culture and Measurements of NO24
The murine microglial cell line (BV2) was cultured in Dulbecco’s modified Eagle medium
(Gibco, USA) supplemented with 5% fetal bovine serum (Hyclone). Production of NO was
measured by the accumulation of nitrite in the culture medium 24 h after stimulation with
LPS (0.5 μg/mL) by the Griess reagent. NO production was measured in the presence of 1–
50 μM of test drugs. L-NAME (a non-selective NOS inhibitor) was included as a positive
control. Data were calculated as 50% inhibitory concentration (IC50) and expressed as the
mean ± S.E.M. from 3–6 experiments performed on different days.
Measurement of NOX Activity
Activity was measured as ROS production triggered with NADPH (200 μM) or fMLP (2
μM) in the presence of 1–50 μM of test drugs in BV2 cell lysate or PMN. DPI, a NOX
inhibitor, was included as a positive control for NOX inhibition. Methodology was been
previously described.25
Measurement of DPPH Radical-Scavenging Capacity
DPPH radical-scavenging capacity assay was performed as in our previous report.19 Briefly,
drugs were diluted in MeOH into a range of concentrations (10–50 μM). DPPH solution
(200 μL; 200 μM in MeOH) was added to 10 μL of each diluted sample in a 96-well
microplate, and the resulting solution was allowed to react for 30 min in the dark at ambient
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temperature. The absorbance caused by the DPPH·radical at 517 nm was determined by a
microplate-spectrophotometer. The radical scavenging capacity was expressed as delta
OD517 (ΔOD517), and values were the means of three replicates. Trolox, an antioxidant, was
included as a reference.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
1H NMR Data for Compounds 1–4 (in Pyridine-d5)
position 1a 2a 3a 4b
1 1.93 m 1.85 m 2.10 td (13.2, 3.2) 1.50 m
2.78 m 2.85 m 3.04 dt (13.2, 3.2) 3.28 m
2 1.86 m 1.86 m 1.92 m 2.40 m
1.93 m 1.89 m 2.74 m 2.52 m
3 3.89 d (1.6)c 3.91 d (2.4) 4.02 br s
4 1.64 m 1.62 m 2.39 m
5 2.13 m 2.02 m 2.65 m 1.50 m
6 1.74 m 1.67 m 2.90 dd (13.2, 3.2) 2.23 m
2.42 m 2.39 m 3.14 t (13.2) 2.51m
7 4.52 t (8.4) 4.50 t (8.4) 4.98 t (8.4)
12 4.44 s 2.43 d (13.2) 2.46 d (13.2) 2.74 d (15.8)
2.95 d (13.2) 2.97 d (13.2) 2.89 d (15.8)
14 3.57 dd (12.0, 6.8) 2.66 dd (12.0, 6.0) 2.67 m
15 2.19 m 2.01 m 1.66 m 1.80 m
2.50 m 2.49 m 2.74 m
16 1.42 m 1.45 1.44 1.60 m
1.83 m
17 2.42 m 1.43 m 1.42 m 1.75 m
18 0.90 s 0.88 s 0.72 s 1.22 s
19 1.57 s 1.49 s 1.99 s 1.45 s
20 1.41 m 1.40 m 1.38 1.56 m
21 1.11 d (7.6) 0.89 d (7.6) 0.87 d (5.2) 1.01 d (6.5)
22 1.37 m 1.31 m 1.30 m 1.27 m
1.81 m 1.75 m 1.75 m 1.88 m
2.25 m 2.20 m 2.20 m 2.23 m
2.44 m 2.39 m 2.38 m 2.42 m
25 3.45 q (6.8) 3.45 q (7.2) 3.45 q (7.2) 3.44 q (7.2)
27 1.48 d (7.2) 1.49 d (6.8) 1.49 d (7.2) 1.47 d (7.2)
28 5.07 s 5.06 s 5.06 s 5.06 s
5.23 s 5.22 s 5.23 s 5.21 s
29 1.18 d (6.8) 1.18 d (6.4) 1.61 s 1.11 d (6.6)
a
Recorded at 400 MHz at 25 °C.
b
Recorded at 500 MHz at 25 °C.
c
J values (in Hz) in parentheses.
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Table 4






















19 >20 (34) >20 (18)
etoposide 4.5 >36
a
NA; Not active. No growth inhibition at 20 μM.
b
Values in parentheses are % inhibition at 20 μM.
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Table 5
Effects of Compounds 2, 6, 9, and 10–22 on NOX Activitya in Murine Microglial Cells and PMN and on NOS
Activityb in Murine Microglial Cells
Compound
IC50 (μM) in NOX
IC50 (μM) in NOSactivity from BV2 cell lysate fMLP-induced NOX activation in PMN
2 NA 32.1 ± 3.5* 15.7 ± 0.9*
6 NA 11.2 ± 2.3* 2.5 ± 0.6*
9 NA 17.5 ± 3.9* 12.7 ± 2.2*
10 NA 15.8 ± 4.0* 1.6 ± 0.6*
11 NA 22.1 ± 6.7* 3.6 ± 0.8*
12 NA NA 9.6 ± 0.7*
13 40.3 ± 3.5* NA 16.2 ± 0.9*
14 NA 8.4 ± 2.1* 0.6 ± 0.3*
15 45.9 ± 7.9* 29.2 ± 6.7* 4.1 ± 0.5*
16 NA 22.6 ± 3.3* 4.2 ± 1.2*
17 NA 47.2 ± 8.4* NA
18 16.0 ± 8.1* 18.1 ± 5.9* 2.5 ± 0.3*
19 NA 21.9 ± 6.3* 22.3 ± 2.9*
20 NA 27.9 ± 5.6* 30.6 ± 0.8*
21 NA 16.2 ± 4.3* 1.5 ± 0.7*
22 NA 20.3 ± 6.4* 6.3 ± 1.8*
DPI 0.4 ± 0.2 0.3 ± 0.1 –
L-NAME – – 25.8 ± 2.5
a
NOX activity was measured as ROS production triggered with NADPH (200 μM) or fMLP (2μM) in the presence of 1–50 μM of test drugs in
BV2 cell lysate or peripheral human neutrophils (PMN). DPI, a NOX inhibitor, was included as a positive control for NOX inhibition.
b
NO production was measured in the presence of 1–50 μM of test drugs. L-NAME (a non-selective NOS inhibitor) was included as a positive
control. Data were calculated as 50% inhibitory concentration (IC50) and expressed as the mean ± S.E.M. from 3–6 experiments performed on
different days using BV2 cell lysate or PMN from different passages or donors. NA: not active.“–”: samples not tested
*
P < 0.05 as compared with relative positive control, respectively.
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